Skip to main content

Table 3 CDK5 expression associated with the various clinicopathological parameters in lung cancer

From: An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker

Lung cancer n CDK5 negative (n, %) CDK5 positive (n, %) Z P
Gender     −0.884 0.377
 Male 275 137(49.8) 138(50.2)   
 Female 90 40(44.4) 50(55.6)   
Age(years)     −0.418 0.676
 <60 196 96(49.0) 100(51.0)   
 ≥60 169 81(47.9) 88(52.1)   
Pathological grading     25.060a <0.001
 I 39 29(74.4) 10(25.6)   
 II 92 53(57.6) 39(42.4)   
 III 131 44(33.6) 87(66.4)   
TNM     −2.944 0.003
 I–II 299 156(52.2) 143(47.8)   
 III–IV 63 20(31.7) 43(68.3)   
LNM     −7.080 <0.001
 Yes 128 30(23.4) 98(76.6)   
 No 234 146 (62.4) 88(37.6)   
Tumor diameter (cm)     −1.653 0.098
 ≤7 314 158(50.3) 156(49.7)   
 >7 48 18(37.5) 30(62.5)   
Distal metastasis     −1.931 0.054
 Absent 346 172(49.7) 174(50.3)   
 Present 16 4(25.0) 12(75.0)   
  1. aKruskal-Wallis H test was performed between the groups of pathological grading